PYC 003
Alternative Names: PYC-003Latest Information Update: 13 May 2025
At a glance
- Originator PYC Therapeutics
- Class Antisense oligonucleotides; Drug conjugates; Morpholines; Peptide drug conjugates
- Mechanism of Action RNA interference; SHANK3 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autosomal dominant polycystic kidney disease
- Preclinical Telomeric 22q13 Monosomy Syndrome
Most Recent Events
- 04 Apr 2025 Phase-I clinical trials in Autosomal dominant polycystic kidney disease (In adults) in Australia (IV) (NCT06714006)
- 28 Feb 2025 PYC Therapeutics files an IND application with the US FDA in USA for Polycystic kidney disease, prior to February 2025
- 28 Feb 2025 US FDA approves IND application for PYC 003 in Polycystic kidney disease